Latest Regulatory Approvals News

Patronus Resources reports significant drilling progress across its Western Australia and Northern Territory projects, with strong assay results at Mertondale and a robust cash position supporting ongoing exploration.

OncoSil Medical has secured new distribution agreements across key international markets and achieved critical regulatory milestones, while raising $8 million to fuel its growth in pancreatic cancer treatment.

Bio-Gene Technology Limited has advanced its bio-insecticide pipeline with two U.S. Department of Defense grants totaling A$3 million, alongside key regulatory and production milestones for Flavocide® and Qcide®.

NGX Limited reports significant progress in its uranium exploration in Namibia and graphite development in Malawi, alongside strategic leadership changes and a strong financial position.

Arafura Rare Earths has secured a pivotal A$200 million investment commitment from the National Reconstruction Fund Corporation, advancing its Nolans Project towards a final investment decision targeted for mid-2025.

Moab Minerals reports significant progress in its uranium exploration portfolio, including pending drill results at Manyoni, acquisition of strategic tenements in Tanzania, and permitting for a follow-up drill program at the REX project in Colorado.

Torque Metals and Aston Minerals have updated shareholders on their merger, confirming the share exchange ratio and appointing an independent expert to assess the deal's fairness.

Tissue Repair Limited has commenced patient randomisation in its Phase 3 trial of TR987®, targeting chronic venous leg ulcers, aiming to confirm promising earlier results and potentially transform wound healing treatment.

New Murchison Gold Limited reports a significant 39% increase in indicated gold resources at its Crown Prince deposit and secures a strategic ore purchase deal with Westgold, setting the stage for mining to commence mid-2025.

InVert Graphite Limited has secured shareholder approval for a transformative acquisition of a Tanzanian graphite project and rebranded from Dominion Minerals, positioning itself for a strategic relisting on the ASX.

ReNerve Limited has reported a remarkable 260% increase in quarterly sales following its successful IPO, alongside strategic distribution deals in Hong Kong and the Middle East. The company is poised for further growth with upcoming clinical data and product developments.

Artrya Limited reports solid progress on its FDA 510(k) application and secures a A$5 million capital raise, positioning itself for imminent commercial rollout in the US healthcare sector.